Kinevant – Talk Bio

Actionable Insights Powered by AI

Roivant’s Kinevant Discontinues Namilumab Development for Pulmonary Sarcoidosis After Phase 2 Failure

2 months ago talkbio0Tagged Drug Development, Failure (biologic function), Kinevant, namilumab, Phase 2 clinical trial, Roivant, Sarcoidosis, Pulmonary

Roivant Sciences, Kinevant, namilumab, pulmonary sarcoidosis, Phase 2 clinical trial, RESOLVE-Lung study, drug development failure

Kinevant Sciences Discontinues Namilumab Development for Pulmonary Sarcoidosis Following Phase 2 Failure

5 months ago talkbio0Tagged Anti-GM-CSF, Kinevant, Monoclonal Antibodies, namilumab, Phase 2 Clinical Trials, Sarcoidosis, Pulmonary, Science

Namilumab, Pulmonary Sarcoidosis, Phase 2 Study, Kinevant Sciences, RESOLVE-Lung Study, Anti-GM-CSF Monoclonal Antibody